European Investment Bank and European Commission Partner with BioNTech for mRNA Vaccine Manufacturing Facility in Rwanda

Strategic Insights -

The European Investment Bank (EIB) and the European Commission (EC) have teamed up with BioNTech to support the development of a messenger RNA (mRNA) vaccine manufacturing facility in Kigali, Rwanda. The project aims to strengthen Africa's ability to produce investigational or approved vaccines for a range of infectious diseases, supporting health, jobs, and innovation. The facility will utilize BioNTech's "BioNTainers" – high-tech, modular units that can quickly be set up and adapted to produce different mRNA vaccines. This flexible approach will enable vaccines to be tailored to local needs, helping to build a resilient vaccine ecosystem in Africa.

Key Takeaways:

  • The EIB and EC will provide up to €95 million in blended financing to support BioNTech's mRNA manufacturing site in Kigali, Rwanda.
  • The facility will use BioNTech's "BioNTainers" – high-tech, modular units that can quickly be set up and adapted to produce different mRNA vaccines.
  • The project is expected to make a significant contribution to several United Nations Sustainable Development Goals (SDGs), especially SDG 3: Good Health and Well-being, SDG 9: Industry, Innovation and Infrastructure, and SDG 10: Reduced Inequalities.
  • BioNTech's Kigali site could become the first commercial mRNA vaccine facility on the continent if successful.
  • The facility is designed to produce mRNA vaccines for diseases that matter most to Africa, such as malaria, tuberculosis, HIV, and mpox, if successfully developed and approved.
  • The project supports the EU's Global Gateway strategy and aligns with the African Union's goal for the continent to produce 60% of its vaccines by 2040.
  • CEPI's support, including a grant of up to €130 million announced in 2024, helps ensure that vaccines produced at the Kigali site will be accessible and affordable for those who need them most.
  • The project aims to build skills, create jobs, and strengthen Rwanda's role as a hub for medical innovation.

Statistics:

  • Up to €95 million in blended financing will be provided by the EIB and EC to support BioNTech's mRNA manufacturing site in Kigali, Rwanda.
  • The facility will have the capacity to produce vaccines for widespread use and support clinical development by manufacturing clinical trial materials for local partners.
  • €1.9 billion has been invested by the EU in local vaccine and medicine manufacturing and affordable access in Africa.
  • BioNTech has made a triple digit million Euro investment in the establishment of its mRNA manufacturing facility in Kigali.
  • The EIB signed nearly €89 billion in new financing for over 900 high-impact projects in 2024.
  • The EIB's health investment totalled €2.9 billion last year and improved healthcare services for more than 7 million people worldwide.

Sources:

  • European Investment Bank
  • European Commission
  • BioNTech
  • CEPI (Coalition for Epidemic Preparedness Innovations)